Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALENTINE-PTCL01 valemetostat monotherapy study in relapsed/refractory PTCL and ATL
jRCT2071200095Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of valemetostat in peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia-lymphoma (ATLL) (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate and Treatment-emergent adverse events. Started Jun 2021; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2071200095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200095.